MCID: MLG079
MIFTS: 50

Malignant Pleural Mesothelioma malady

Categories: Cancer diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

Aliases & Descriptions for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 14 69
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 52

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
ICD10 33 C45.0
NCIt 47 C7376
UMLS 69 C0812413

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to mesothelioma, somatic and testicular malignant germ cell cancer, and has symptoms including chest pain, dyspnea and fatigue. An important gene associated with Malignant Pleural Mesothelioma is SPP1 (Secreted Phosphoprotein 1), and among its related pathways/superpathways are Pathways in cancer and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Alimta and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and endothelial, and related phenotypes are cellular and cardiovascular system

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Related Disease Score Top Affiliating Genes
1 mesothelioma, somatic 11.2
2 testicular malignant germ cell cancer 10.3 CDKN2A WT1
3 thymus lipoma 10.3 CALB2 WT1
4 thymic dysplasia 10.2 CALB2 MUC1
5 lung cancer 10.2
6 gestational trophoblastic neoplasm 10.2 CALB2 MUC1 WT1
7 hyperandrogenism 10.2 CALB2 MSLN THBD
8 cleft palate cardiac defect ectrodactyly 10.2 BAP1 EGFR MET
9 orofaciodigital syndrome 13 10.2 EGFR PDPN
10 immunodeficiency due to a classical component pathway complement deficiency 10.2 BIRC5 CDKN2A EGFR MUC1
11 ovarian insufficiency due to fsh resistance 10.2 MET MUC1 SPP1
12 paroxysmal nocturnal hemoglobinuria 10.2 CDKN2A EGFR MSLN MUC1
13 sphenoid sinus squamous cell carcinoma 10.2 CALB2 NKX2-1 THBD
14 pearson syndrome 10.2 CDKN2A EGFR MSLN MUC1
15 eccrine sweat gland neoplasm 10.2 BAP1 THBD WT1
16 trachea squamous cell carcinoma 10.2 CDKN2A EGFR MSLN MUC1
17 lower lip cancer 10.2 BIRC5 EGFR MET
18 cranial nerve disease 10.2 CALB2 NKX2-1 THBD
19 dental caries 10.2 EGFR MSLN MUC1 WT1
20 nasal cavity disease 10.2 EGFR MSLN MUC1 WT1
21 progesterone-receptor positive breast cancer 10.1 CDKN2A EGFR MUC1
22 combined thymoma 10.1 CALB2 EGFR MUC1 NKX2-1
23 allergic contact dermatitis 10.1 CDKN2A EGFR MUC1 NKX2-1
24 myotonic disease 10.1 CALB2 THBD WT1
25 adenocarcinoma 10.1
26 endotheliitis 10.1
27 occlusion precerebral artery 10.1 CDKN2A EGFR MUC1
28 statin toxicity 10.1 BIRC5 CALB2 PDPN
29 brown-vialetto-van laere syndrome 10.1 EGFR MUC1 NKX2-1 WT1
30 persian gulf syndrome 10.1 CALB2 MSLN THBD WT1
31 sengers syndrome 10.1 CDKN2A EGFR MET MUC1
32 estrogen-receptor positive breast cancer 10.1 CDKN2A EGFR PDPN
33 mesenteric vascular occlusion 10.1 CALB2 PDPN WT1
34 non-distal monosomy 10q 10.1 CDKN2A EGFR MET NKX2-1
35 proctitis 10.1 CDKN2A EGFR MET TYMS
36 ovarian papillary neoplasm 10.1 CALB2 MSLN MUC1 THBD
37 diabetes persistent mullerian ducts 10.1 MUC1 THBD WT1
38 petrous apex meningioma 10.1 CALB2 MUC1 THBD WT1
39 amyloidosis, hereditary, transthyretin-related 10.0 CALB2 MET MUC1
40 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.0 CALB2 CDKN2A EGFR MSLN MUC1 NKX2-1
41 gastroesophageal junction adenocarcinoma 10.0 CDH2 EGFR MUC1
42 tumor of exocrine pancreas 10.0 CDKN2A EGFR MUC1 THBD WT1
43 pneumothorax 10.0
44 mediastinitis 10.0
45 tenosynovitis of foot and ankle 10.0 MET MUC1 NKX2-1
46 chondroblastoma 10.0 CALB2 MUC1 NKX2-1 THBD WT1
47 kidney benign neoplasm 10.0 BIRC5 CEACAM3 MUC1
48 avian influenza 10.0 CDKN2A MUC1 NKX2-1 THBD WT1
49 skeletal-extraskeletal angiomatosis 9.9 CEACAM3 MUC1
50 malignant pleural solitary fibrous tumor 9.9 CDKN2A EGFR MUC1 NKX2-1 PDPN

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 PPP1R15A SPP1 THBD TXN WT1 XIAP
2 cardiovascular system MP:0005385 10.26 BAP1 CDH2 CDKN2A EGFR MET NKX2-1
3 growth/size/body region MP:0005378 10.23 BAP1 CDH2 CDKN2A EGFR MET NKX2-1
4 homeostasis/metabolism MP:0005376 10.18 BAP1 BIRC5 CDH2 CDKN2A EGFR MET
5 mortality/aging MP:0010768 10.17 EGFR MET NKX2-1 PDPN PPP1R15A SPP1
6 embryo MP:0005380 10.13 BAP1 BIRC5 CDH2 CDKN2A EGFR MET
7 hematopoietic system MP:0005397 10.13 BAP1 BIRC5 CDKN2A EGFR PDPN PPP1R15A
8 immune system MP:0005387 10.11 CDKN2A EGFR MET PDPN PPP1R15A SPP1
9 digestive/alimentary MP:0005381 10.04 BAP1 CDKN2A EGFR MET NKX2-1 PDPN
10 muscle MP:0005369 9.91 BAP1 CDH2 CDKN2A EGFR MET PDPN
11 neoplasm MP:0002006 9.7 BAP1 CDKN2A EGFR MET NKX2-1 SPP1
12 normal MP:0002873 9.65 MSLN NKX2-1 PPP1R15A THBD WT1 XIAP
13 respiratory system MP:0005388 9.28 BAP1 CDKN2A EGFR MET NKX2-1 PDPN

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Alimta 17 46 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 5460373 44475014
8
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Raltitrexed Approved, Investigational Phase 3,Phase 1,Phase 2 112887-68-0 104758
12
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
13
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
14
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
15
Nintedanib Approved Phase 3,Phase 2 656247-17-5 56843413
16
nivolumab Approved Phase 3,Phase 2 946414-94-4
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
19
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21 Ranpirnase Investigational Phase 3 196488-72-9
22 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
23 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
24 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
25 Topoisomerase Inhibitors Phase 3,Phase 2
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
27 Trace Elements Phase 3,Phase 2
28 Dexamethasone 21-phosphate Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
30 Vitamin B 12 Phase 2, Phase 3
31 Vitamin B Complex Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Vitamins Phase 2, Phase 3
34 Anti-Infective Agents Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Antiemetics Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 3,Phase 2,Phase 1
41 Micronutrients Phase 3,Phase 2
42 BB 1101 Phase 3,Phase 2,Phase 1
43 Autonomic Agents Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 3,Phase 2,Phase 1
46 Analgesics Phase 3,Phase 2,Phase 1
47 Alkylating Agents Phase 3,Phase 2,Phase 1
48 Mitomycins Phase 3
49 Histone Deacetylase Inhibitors Phase 3,Phase 2,Phase 1
50 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 199)
id Name Status NCT ID Phase
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3
2 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3
3 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3
4 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3
5 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3
6 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3
7 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3
8 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3
9 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
10 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3
11 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Recruiting NCT01604005 Phase 3
12 Nintedanib (BIBF 1120) in Mesothelioma Recruiting NCT01907100 Phase 3
13 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Recruiting NCT02899299 Phase 3
14 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Active, not recruiting NCT01098266 Phase 3
15 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Not yet recruiting NCT02991482 Phase 3
16 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2
17 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2
18 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2
19 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2
20 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2
21 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2
22 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2
23 ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. Approved for marketing NCT00040625 Phase 2
24 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2
25 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
26 Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00484276 Phase 2
27 Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2
28 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2
29 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment Completed NCT01243632 Phase 2
30 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2
31 Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. Completed NCT02004028 Phase 2
32 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) Completed NCT00700336 Phase 1, Phase 2
33 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Completed NCT01112293 Phase 2
34 Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2
35 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2
36 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00513877 Phase 2
37 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2
38 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2
39 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2
40 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Completed NCT00738582 Phase 2
41 Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma Completed NCT00407459 Phase 2
42 Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00004033 Phase 2
43 A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. Completed NCT00996567 Phase 2
44 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Completed NCT00770120 Phase 2
45 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00101283 Phase 2
46 Isolated Thoracic Perfusion (ITP-F) for MPM Completed NCT02467426 Phase 2
47 Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Completed NCT00165516 Phase 2
48 Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma Completed NCT01211275 Phase 1, Phase 2
49 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma Completed NCT00087698 Phase 2
50 Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma Completed NCT00054002 Phase 2

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

39
Lung, Testes, Endothelial, T Cells, Bone, Lymph Node, Monocytes

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 783)
id Title Authors Year
1
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence. ( 27979596 )
2017
2
Asbestos fibres detected by scanning electron microscopy in the gallbladder of patients with malignant pleural mesothelioma (MPM). ( 28066892 )
2017
3
Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. ( 28027744 )
2017
4
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. ( 27881012 )
2017
5
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. ( 28027772 )
2017
6
Open access phone triage for veterans with suspected malignant pleural mesothelioma. ( 27979465 )
2017
7
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : AA propensity score matching of the SEER database. ( 28044200 )
2017
8
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment. ( 28051015 )
2017
9
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma. ( 26440572 )
2016
10
Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. ( 28003305 )
2016
11
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma. ( 27197170 )
2016
12
208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial. ( 27198358 )
2016
13
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. ( 27584578 )
2016
14
Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions. ( 27663394 )
2016
15
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review. ( 27057918 )
2016
16
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. ( 26762744 )
2016
17
Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent. ( 26773069 )
2016
18
Recurrent hydropneumothorax: An unusual presentation for malignant pleural mesothelioma. ( 27489758 )
2016
19
Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor. ( 27660729 )
2016
20
The use of electron microscopy for the diagnosis of malignant pleural mesothelioma. ( 28066639 )
2016
21
Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System. ( 27509983 )
2016
22
KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. ( 26780987 )
2016
23
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia. ( 27198346 )
2016
24
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. ( 27094927 )
2016
25
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma. ( 27853379 )
2016
26
SU-F-T-391: Comparative Study of Treatment Planning Between IMRT and IMAT for Malignant Pleural Mesothelioma. ( 28047252 )
2016
27
Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway. ( 27176604 )
2016
28
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. ( 27512118 )
2016
29
Malignant pleural mesothelioma in a young adult with no known exposure to asbestos. ( 27156205 )
2016
30
Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique. ( 27926627 )
2016
31
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. ( 27543082 )
2016
32
209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. ( 27198344 )
2016
33
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). ( 27133741 )
2016
34
Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion. ( 27501894 )
2016
35
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature. ( 27993826 )
2016
36
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. ( 27646775 )
2016
37
c-Met expression and MET amplification in malignant pleural mesothelioma. ( 27402216 )
2016
38
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma. ( 27932892 )
2016
39
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma. ( 27074478 )
2016
40
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. ( 26824986 )
2016
41
Harnessing the Power of the Host: Improving Dendritic Cell Vaccines for Malignant Pleural Mesothelioma. ( 27128703 )
2016
42
North American Multicenter Volumetric CT study For Clinical Staging Of Malignant Pleural Mesothelioma: Feasibility And Logistics Of setting up a Quantitative imaging Study. ( 27180318 )
2016
43
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. ( 27867002 )
2016
44
Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma. ( 27091358 )
2016
45
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? ( 27597274 )
2016
46
Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. ( 27009350 )
2016
47
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis. ( 27198347 )
2016
48
Erratum: Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea. ( 27587973 )
2016
49
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. ( 27596916 )
2016
50
Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study. ( 27117437 )
2016

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.15 BIRC5 CDKN2A EGFR MET XIAP
2 11.48 BAP1 CDH2 SPP1
3 11.3 BIRC5 CDKN2A XIAP
4 10.83 CDH2 EGFR TXN
5 10.47 CDH2 MET SPP1

GO Terms for Malignant Pleural Mesothelioma

Cellular components related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 CDH2 EGFR MET MSLN THBD

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lung development GO:0030324 9.5 EGFR NKX2-1 PDPN
2 positive regulation of bone resorption GO:0045780 9.26 EGFR SPP1
3 cerebral cortex cell migration GO:0021795 9.16 EGFR NKX2-1
4 cell proliferation GO:0008283 9.02 EGFR MET PDPN TXN TYMS
5 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 8.96 BIRC5 XIAP

Molecular functions related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.92 CDH2 EGFR MET PPP1R15A

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....